Please assess the completion status of the following clinical trial:

Trial Title: suPERficial Slow-flow Vascular malFORMations Treated With sirolimUS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* Patients aged from 6 years to 18 years~* With a slow-flow vascular malformation confirmed by MRI, included or not into a genetic disorder, among the following:~* microcystic lymphatic malformation~* mixed micro- and macrocystic malformation~* venous malformation~* combined lymphatic and venous malformation~* Malformation voluminous and complicated (pain, functional impairment, bleeding, seepage)~* Extended to the underlying subcutaneous tissue, to the fascias, the muscles and/or the underlying bone~* MRI of the VM performed within 8 months~* Vaccination schedule updated~* Informed, written consent of the subject's parents or the 18 years old subject~* Cooperative parent or subject, aware of the necessity and duration of controls so that perfect adhesion to the protocol could be expected~* Subjects or subject's parents covered by or having the rights to social security.~Exclusion criteria:~* Slow-flow VMs which are only macrocystic lymphatic malformations~* Visceral life-threatening involvement~* Patients who received prior per os treatment with an mTOR inhibitor~* Immunosuppression (immunosuppressive disease or immunosuppressive treatment)~* Known chronic infectious disease~* History of cancer in the 2 previous years~* Brest feeding or pregnant women, or women on childbearing age without effective contraception, up to 12 weeks after treatment discontinuation~* Known allergy to mTOR inhibitor~* Concomitant treatment that inhibits or activates CYP3A4, and P-gp glycoprotein, cytotoxic drugs, antilymphocyte immunoglobulines and metoclopramide~* Intolerance to fructose, intolerance or malabsorption to glucose, galactose, metabolic insufficiency in sucraseisomaltase, metabolic defect in lactase~* Known allergy to peanuts or soyabean~* Liver insufficiency (elevated transaminases \> 2.5 N)~* Anemia with Hb \< 9 g/dl~* Leukopenia \< 1000/mm3~* Thrombocytopenia \< 80 000/mm3~* Hypercholesterolemia (LDL-cholesterol ≥ 2g/l)~* Patients with risk of opportunistic infections~* Contraindication of MRI~* Known allergy to lidocaïne~* Live attenuated vaccine up to 3 months after sirolimus discontinuation~* Subject already participating to a therapeutic study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Observational (Type: NO_INTERVENTION): Patients will first be included in an observational period, then, at a randomized time different from one to another, will all receive the experimental treatment (i.e. sirolimus).~This design has been defined a the randomized placebo-phase design (Feldman et al. J Clin Epidemiol. 2001 Jun;54(6):550-7)
- Experimental (Type: EXPERIMENTAL): At a randomized date, patients will start treatment with sirolimus (beginning dose: 0.08mg/kg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).